Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

This phase I trial tests the safety, side effects, and best dose of decitabine in combination with standard of care surgery, radiation, and/or chemotherapy and the effectiveness of the combination in treating patients with head and neck squamous cell cancers that are not caused by human papilloma virus (HPV-negative) and that can be removed by surgery (resectable). Decitabine, an antimetabolite, stops cells from making deoxyribonucleic acid (DNA) and may kill tumor cells. Studies have shown that medications like decitabine can make some types of solid tumors more sensitive to chemotherapy. Thi

Trial Details

NCT ID

NCT06997094

Phase

PHASE1

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Biospecimen Collection
Chemotherapy
Decitabine
External Beam Radiation Therapy
Questionnaire Administration
Surgical Procedure

Locations (sample)

Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

REGISTRATION: Age ≥ 18 years
REGISTRATION: Histologic confirmation of HPV-negative, squamous cell carcinoma of the head and neck that is surgically resectable. HPV-status confi…
Includes mucosal and non-mucosal subsites
Includes head and neck of unknown primary origin REGISTRATION: Measurable disease preoperatively, as defined by Response Evaluation Criteria in Sol…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →